Managing Director, Healthcare Investment Banking, Life Sciences
Current• Life Science Tools, Services and Diagnostics coverage focus• $120Bn+ in closed M&A advisory and acquisition financing transactions• $5Bn+ in bookrun equity and equity-linked capital markets transactions, including active bookrunner roles on landmark initial public offerings• $25Bn+ in bookrun debt capital markets transactions, encompassing a range of investment grade and high yield senior debt, subordinated / hybrid debt, perpetual preferred and term loan offerings, as well as broader liability management engagements